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Original Article
Blood pressure targets for hypertension in patients with type 2 
diabetes 
Wilbert S. Aronow1, Tatyana A. Shamliyan2
1Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, USA; 2Quality Assurance, Evidence-Based 
Medicine Center, Elsevier, Philadelphia, PA, USA
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Elsevier 1600 JFK Blvd, Philadelphia, PA 19103, USA. Email: t.shamliyan@elsevier.com.
Background: Clinical guidelines vary in determining optimal blood pressure targets in adults with diabetes 
mellitus. 
Methods: We systematically searched PubMed, EMBASE, Cochrane Library, and clinicaltrials.gov in 
March 2018; conducted random effects frequentist meta-analyses of direct aggregate data; and appraised 
the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) methodology.
Results: From eligible 14 meta-analyses and 95 publications of randomized controlled trials (RCT), only  
6 RCTs directly compared lower versus higher blood pressure targets; remaining RCTs aimed at comparative 
effectiveness of hypotensive drugs. In adults with diabetes mellitus and elevated systolic blood pressure (SBP), 
direct evidence (2 RCTs) suggests that intensive target SBP <120–140 mmHg decreases the risk of diabetes-related 
mortality [relative risk (RR) =0.68; 95% confidence interval (CI), 0.50–0.92], fatal (RR =0.41; 95% CI, 0.20–0.84)  
or nonfatal stroke (RR =0.60; 95% CI, 0.43–0.83), prevalence of left ventricular hypertrophy and 
electrocardiogram (ECG) abnormalities, macroalbuminuria, and non-spine bone fractures, with no differences 
in all-cause or cardiovascular mortality or falls. In adults with diabetes mellitus and elevated diastolic 
blood pressure (DBP) ≥90 mmHg, direct evidence (2 RCTs) suggests that intensive DBP target ≤80 versus  
80–90 mmHg decreases the risk of major cardiovascular events. Published meta-analyses of aggregate 
data suggested a significant association between lower baseline and attained blood pressure and increased 
cardiovascular mortality.
Conclusions: We concluded that in adults with diabetes mellitus and arterial hypertension, in order 
to reduce the risk of stroke, clinicians should target blood pressure at 120–130/80 mmHg, with close 
monitoring for all drug-related harms. 
Keywords: Quality of evidence; cardiovascular morbidity; diabetes mellitus; arterial hypertension; blood pressure 
targets
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Introduction
One of the main goals in managing type 2 diabetes in adults 
is prevention of cardiovascular morbidity or mortality by 
controlling blood glucose, normalizing blood pressure, and 
reducing other cardiovascular risk factors (1,2). Despite 
extensive review of literature, clinical practice guidelines 
vary in determining the optimal blood pressure targets in 
patients with diabetes (3-5).
To support clinical decisions at point of care with all 
available evidence, we conducted a rapid review of the 
published and unpublished data from recently completed 
randomized controlled trials (RCT), meta-analyses of 
RCTs, and primary observational studies that compared 
different blood pressure targets in adults with diabetes.
Methods
We used a standard recommended methodology in 
conducting systematic literature reviews and meta-analyses 
from the Cochrane Collaboration and the Agency for 
Healthcare Research and Quality (6,7). We developed 
a priori protocol (available by request) for a systematic 
literature review to answer the clinical question about 
the comparative effectiveness of blood pressure targets 
on mortality and cardiovascular morbidity in adults with 
diabetes mellitus.
Eligible studies directly compared lower versus higher 
blood pressure targets or examined the association between 
baseline or attained blood pressure with patient outcomes 
in people treated with hypotensive medications. Eligible 
outcomes included all-cause and underlying cause-specific 
mortality, cardiovascular morbidity, stroke, heart failure, 
renal failure, and all drug harms. 
We conducted a comprehensive search in PubMed, 
EMBASE, the Cochrane Library, and www.clinicaltrials.gov 
up to March 2018 to find systematic reviews, published and 
unpublished RCTs, and nationally represented controlled 
observational studies that reported adjusted effect estimates 
(6,7). The data were extracted from the Clinical Trials 
Transformation Initiative (https://www.ctti-clinicaltrials.
org/aact-database), checked for quality, and stored in 
the High-Performance Computing Cluster platform 
(https://hpccsystems.com). 
We tested the null hypotheses of no differences in patient 
outcomes after more versus less extensive blood pressure 
lowering (6). We abstracted the information about study 
population, interventions, comparators, and outcomes (6). 
We abstracted minimum datasets (e.g., number of the 
subjects in treatment groups and events) to estimate 
absolute risk difference, relative risk, and number needed to 
treat for categorical variables (6). Statistical significance was 
evaluated at a 95% confidence level (including the use of 
P values). 
We conducted a rapid review following the framework 
of the AHRQ (8). We used the AHRQ recommended 
methodological approach in the integration of existing 
systematic reviews into our comprehensive synthesis of 
evidence (9). Our goal was the integration of previously 
published high quality reviews and consistent ranking of the 
quality of evidence using GRADE methodology. 
We performed meta-analyses when definitions of active 
and control interventions and patient outcomes deem 
similar (10). We examined consistency in results across 
studies with chi-square tests and I2 statistics and concluded 
statistically significant heterogeneity if I2 was >50% (6). 
Statistically significant heterogeneity did not preclude 
statistical pooling (10). However, we planned exploring 
heterogeneity with a priori defined patient baseline 
hypertensive status (10).
We defined harms as the totality of all possible adverse 
consequences of an intervention. 
We calculated absolute risk difference, number needed 
to treat, and the number of attributable events based on 
data from the published randomized trials, using STATA 
software (StataCorp LP, College Station, TX, USA) (11). 
Correction coefficients for zero events were used as 
a default option, and intention to treat was used for 
evidence synthesis (10). Superiority of interventions under 
comparison was hypothesized (12). We used consensus 
method guidelines for systematic review and meta-analyses 
that do not recommend conducting post hoc analyses of 
statistical power (13-15). Instead, we downgraded our 
confidence in true treatment effects based on calculated 
optimal information size as the number of patients required 
for an adequately powered individual trial (16). Since power 
is more closely related to number of events than to sample 
size, we concluded imprecision in treatment effects if less 
than 250 patients experienced the event (16).
We assessed reporting bias as a proportion of published 
among all registered studies, unreported outcomes 
compared with published protocols, or unreported 
minimum data sets for reproducibility of the results (17). 
We did not conduct formal statistical tests for publication 
bias due to the questionable validity of such tests (18).
We evaluated the quality of the primary studies using 
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the Cochrane risk of bias tool on a 3-point scale: high bias, 
low bias, and unclear (6). We upgraded the risk of bias in 
the body of evidence from low to high if at least 1 RCT 
had high risk of bias (19,20). We defined indirectness in 
outcomes from intermediate outcomes (21).
Treatment effect estimates were defined as precise when 
pooled estimates had reasonably narrow 95% confidence 
intervals (CI) and the number of events were greater than 
250 (22). Justification of the sample size was not included in 
grading of the evidence. 
In assessing the quality of evidence in all studies, the 
authors looked for the strength of association and evidence 
of any reporting bias (23). The strength of the association 
was evaluated, defining a priori a large effect when the 
relative risk was greater than 2 and a very large effect when 
the relative risk was greater than 5 (23). A small treatment 
effect was construed when the relative risk was significant 
but less than 2 (23).
The authors assigned the quality of evidence ratings as 
high, moderate, low, or very low, according to risk of bias in 
the body of evidence, directness of comparisons, precision 
and consistency in treatment effects, and the evidence 
of reporting bias, using Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
methodology (Supplementary file) (23). A high quality 
of evidence was assigned to well-designed RCTs with 
consistent findings. The quality of evidence was downgraded 
to moderate if at least 1 of 4 quality of evidence criteria 
were not met; for example, moderate quality of evidence 
was assigned if there was a high risk of bias in the body of 
evidence or if the results were not consistent or precise (23). 
The quality of evidence was downgraded to low if 2 or more 
criteria were not met.
A low quality of evidence was assigned to nonrandomized 
studies and upgraded for the rating if there was a strong 
association. Evidence was defined as insufficient when no 
studies provided valid information about treatment effects. 
This approach was applied regardless of whether the results 
were statistically significant.
Results
Our comprehensive search in PubMed, EMBASE, the 
Cochrane Library, and clinicaltrials.gov up to March 2018 
retrieved 306 references and identified 16 publications of 
systematic reviews and meta-analyses and 96 publications 
of RCTs that enrolled adults primarily with type 2 diabetes 
mellitus (Supplementary file, Figure S1). We excluded 
124 irrelevant references at the screening of the titles 
and abstracts and 33 publications after full text review 
because the studies did not address blood pressure targets 
in patients with diabetes (Supplementary file, Figure S1). 
Only 6 primary RCTs randomly assigned patients to lower 
versus higher blood pressure targets and compared systolic 
blood pressure (SBP) targets in patients with baseline 
arterial hypertension (24,25) or diastolic blood pressure 
(DBP) targets in patients with normal (26,27) or elevated 
baseline blood pressure (28,29). All other RCTs compared 
hypotensive drugs with placebo or with each other. Meta-
analyses of such trials explored the association of baseline or 
achieved blood pressure with patient outcomes (3-5,30-39).
In adults with diabetes and normal arterial blood 
pressure, low-quality evidence suggests that there are no 
differences in all-cause and cardiovascular mortality or 
morbidity between intensive (10 mmHg below baseline 
DBP) and moderate blood pressure control (DBP goal 
80–89 mmHg; Table 1). Intensive blood pressure control 
prevents cerebrovascular events and progression or 
retinopathy in some patients (Table 1).
In adults with diabetes and elevated arterial blood 
pressure (DBP ≥90 mmHg), low-quality evidence suggests 
that there are no differences in all-cause and cardiovascular 
mortality or stroke between intensive (DBP ≤85–75 mmHg) 
and moderate  blood pressure control  (DBP goal 
80–90 mmHg; Table 2). A single RCT suggests that a 
reduction of DBP ≤80 mmHg results in a lower risk of 
major cardiovascular events but higher risk of progressing 
neuropathy (Table 2).
In adults with diabetes and elevated arterial blood 
pressure (SBP 130–190 mmHg), moderate-quality 
evidence suggests that there are no differences in all-
cause or cardiovascular mortality between intensive and 
standard blood pressure control (Table 3 and Figure 1). 
However, intensive blood pressure control decreases the 
risk of diabetes-related mortality, fatal or nonfatal stroke 
(Figure 2), prevalence of left ventricular hypertrophy and 
electrocardiogram (ECG) abnormalities, macroalbuminuria, 
and non-spine bone fractures (Table 3). A single RCT 
(ACCORD) suggests that the risk of a composite outcome 
(nonfatal myocardial infarction, nonfatal stroke, and death 
from cardiovascular causes) is lower after intensive blood 
pressure and good glycemic control but higher in adults with 
poorly controlled diabetes (hemoglobin A1c >8.0; Table 3). 
The benefits from intensive blood pressure control sustain 
at 9 years of follow-up in older adults with 15% or greater 
10-year coronary heart risk in the standard glucose control 
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arm of ACCORD trial (Table 3). The same study reported 
an increased risk of adverse effects from hypotensive 
medications, including hypotension or hyperkalemia, after 
intensive blood pressure control (Table 3). 
Primary studies did not address circadian fluctuations in 
blood pressure or the risk of orthostatic hypotension after 
intensive versus standard blood pressure targets. For the 
record, the ACCORD study found no differences in patient 
falls or trauma after intensive blood pressure control (Table 3).
Published meta-analyses of aggregate data from RCTs 
aimed at efficacy or comparative effectiveness of specific 
hypotensive drugs in adults with comorbid diabetes and 
arterial hypertension (baseline blood pressure >150 mmHg) 
agree that attained SBP 130–139 and DBP 75–80 mmHg 
is associated with lower risk of all-cause mortality and 
stroke (Table S1) (5,31,33,37). Systematic reviews and 
guidelines vary in determining the balance between benefits 
and harms of lowering blood pressure below 130 mmHg 
(4,5). We looked at the pooled relative risk of all reported 
outcomes in published reviews (Table S1) and found 2 meta-
analyses that reported a statistically significant increase 
in the risk of cardiovascular mortality in association with 
lower baseline blood pressure (Table S2) (31,37). Anti-
hypertensive treatments are associated with a higher risk of 
cardiovascular mortality per each 10 mmHg lower baseline 
SBP and DBP (Table S2). 
Discussion
Our review found moderate direct quality evidence that 
in adults with diabetes and elevated SBP, intensive blood 
pressure control (target SBP <120–140 mmHg) decreases 
the risk of diabetes-related mortality, fatal or nonfatal 
stroke, prevalence of left ventricular hypertrophy and ECG 
abnormalities, macroalbuminuria, and non-spine bone 
fractures, with no differences in all-cause or cardiovascular 
mortality or falls. 
We downgraded the quality of evidence due to risk 




Attributable avoided events 
per 1,000 treated (95% CI)
Relative measure of association; 
number needed to treat (95% CI)
No. of participants 
(studies)
All-cause mortality** 63/65 NS RR: 0.96 (0.53–1.75);  
HR: 0.96 (0.53–1.75)
609 (2 RCTs) (26,27) 
Cardiovascular 
mortality*
55/37 NS RR: 1.48 (0.65–3.40) 480 (1 RCT) (27,40)
Non-cardiovascular 
mortality*
21/45 NS RR: 0.47 (0.16–1.32) 480 (1 RCT) (27,40)
Cardiovascular 
event**
73/56 NS RR: 1.31 (0.71–2.42) 609 (2 RCTs) (26,27)
Congestive heart 
failure*
51/45 NS RR: 1.12 (0.50–2.49) 480 (1 RCT) (27,40)
Myocardial 
infarction*
80/62 NS RR: 1.30 (0.68–2.49) 480 (1 RCT) (27,36)
Cerebrovascular 
accident*
17/53 37 [4–69] RR: 0.32 (0.10–0.95);  
NNTp: 27 [14–255]#
480 (1 RCT) (27,36)
Retinopathy 
progression**
269/369 NR RR: 0.74 (0.60–0.93)# 609 (2 RCTs) (26,27)
Neuropathy 
progression**
349/337 NS RR: 1.04 (0.83–1.29) 609 (2 RCTs) (26,27)
Population: adults with diabetes and normal arterial blood pressure; Settings: outpatient; Intervention: intensive blood pressure control 
(10 mmHg below baseline DBP); Comparator: moderate blood pressure control (DBP goal 80–89 mmHg). #, favors lower blood pressure 
target; *, very low quality evidence; **, low quality evidence. CI, confidence interval; DBP, diastolic blood pressure; GRADE, Grading of 
Recommendations Assessment, Development and Evaluation; HR, hazard ratio; NNTp, number needed to treat to prevent an outcome in 
one patient; RCT, randomized controlled trial; RR, relative risk; NS, no statistically significant difference; NR, not reported.
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of bias, small number of events in the studies, and 
heterogeneity in treatment effects across the studies. We 
did not conduct meta-regression of few RCTs that directly 
compared patient outcomes after intensive versus standard 
blood pressure targets (6). Instead, we reviewed published 
meta-analyses of RCTs aimed at comparative effectiveness of 
blood lowering drugs in adults with diabetes that concluded 
no benefits from lowering blood pressure below 130 mmHg. 
Such publications employed meta-regression of aggregated 
data that can generate hypotheses of potential harms from 
extensive lowering blood pressure control specifically 
in adults with normal baseline blood pressure (45). 
Published meta-analyses that included the data from the 
Systolic Blood Pressure Intervention Trial (SPRINT) 
suggest similar reduction in the risk of major cardiovascular 
events from intensive blood pressure lowering in adults 
with and without diabetes (20,38,46). Individual rather than 
aggregate patient data meta-analyses would provide better 
evidence about the association between specific drugs, 
baseline and achieved blood pressure, and patient outcomes 
independent of drug effects (47).
We found no studies that addressed the risk of 
hospitalization or long-term quality of life in relation to blood 
pressure targets in adults with diabetes. Although orthostatic 
hypotension is associated with poor patient outcomes, 
the evidence regarding the risk of this complication after 
intensive or standard blood pressure control is insufficient 
(3,48,49). Primary studies and meta-analyses did not discuss 
the importance of pulse pressure in reducing morbidity and 
mortality in adults with diabetes (50).
Guidelines recommend healthy diet, weight normalization, 
and physical activity for all adults with diabetes (Table S3) (51-58). 




comparator per 1,000 
Attributable avoided events 
per 1,000 treated (95% CI)
Relative measure of association; 
number needed to treat (95% CI)
No. of participants 
(studies)












44/90 Avoided 46 [15–77] RR: 0.49 (0.30–0.80);  
NNTp: 22 [13–67]#
1,000 (1 RCT) (29)
Major cardiovascular 
events, DBP ≤85*
68/90 NS RR: 0.76 (0.49–1.16) 1,002 (1 RCT) (29)
Any cardiovascular 
event*




25/38 NS RR: 0.78 (0.38–1.61) 1,971 (2 RCTs) 
(28,40)




400/310 Excessive 92 [6–178] RR: 1.30 (1.01–1.66);  
NNT: 11 [6–174]†
470 (1 RCT) (28)
Retinopathy 
progression*
300/340 NS RR: 0.88 (0.68–1.15) 470 (1 RCT) (28)
Population: adults with diabetes and elevated arterial blood pressure (DBP ≥90 mmHg); Settings: outpatient; Intervention: intensive blood 
pressure control (DBP ≤75–85 mmHg); Comparator: moderate blood pressure control (DBP goal 80–90 mmHg). #, favors lower blood 
pressure target; †, favors higher blood pressure target; *, very low quality evidence; **, low quality evidence. CI, confidence interval; DBP, 
diastolic blood pressure; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NNT, number needed to treat; 
NNTp, number needed to treat to prevent an outcome in one patient; RCT, randomized controlled trial; RR, relative risk.
Aronow and Shamliyan. Blood pressure in diabetes
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2018;6(11):199atm.amegroups.com
Page 6 of 13





comparator per 1,000 
Attributable avoided 
events per 1,000 
treated (95% CI)
Relative measure of 
association; number 
needed to treat (95% CI)
No. of participants 
(studies)
All-cause mortality*** 91/82 NS RR: 0.94 (0.75–1.18) 5,881 (2 RCTs) (25,36)
All-cause mortality, 9 years of 
follow-up*
224/234 NS RR: 0.96 (0.78–1.17) 1,284 (1 RCT) (42)
Cardiovascular death, nonfatal MI, 
nonfatal stroke, 9 years of follow-
up*
199/259 Avoided 60 [14–106] RR: 0.77 (0.63–0.94); 
NNTp: 17 [9–70]#
1,284 (1 RCT) (42)
Coronary death, nonfatal MI, 
unstable angina, 9 years of follow-
up*
201/267 Avoided 66 [20–113] RR: 0.75 (0.62–0.92); 
NNTp: 15 [9–49]#
1,284 (1 RCT) (42)
Cardiovascular death, 9 years of 
follow-up*
58/76 NS RR: 0.77 (0.51–1.16) 1,284 (1 RCT) (42)
Fatal myocardial infarction** 21/17 NS RR: 0.80 (0.50–1.28) 5,882 (2 RCTs) (24,25)
Fatal stroke** 4/7 NR RR: 0.41 (0.20–0.84)# 5,882 (2 RCTs) (24,25)
Any stroke** 24/35 Avoided 16 [7–24] RR: 0.58 (0.43–0.78); 
NNTp: 63 [42–143]#
5,881 (2 RCTs) (25,36)
Nonfatal stroke** 20/29 Avoided 12 [4–20] RR: 0.60 (0.43–0.83); 
NNTp: 83 [50–250]#
5,882 (2 RCTs) (24,25)
Nonfatal myocardial infarction** 57/63 NS RR: 0.87 (0.71–1.07) 5,882 (2 RCTs) (24,25)
Non-fatal MI, 9 years of follow-
up*
100/147 Avoided 47 [12–83] RR: 0.68 (0.50–0.91); 
NNTp: 21 [12–87]#
1,284 (1 RCT) (42)
Myocardial infarction, any*** 115/123 NS RR: 0.90 (0.78–1.04) 5,881 (2 RCTs) (25,36)
Cancer death** 23/19 NS RR: 1.17 (0.74–1.84) 5,882 (2 RCTs) (24,25)
Fatal or nonfatal heart failure* 33/41 NS RR: 0.67 (0.34–1.36) 5,882 (2 RCTs) (24,25)
MACE**; subgroup: HbA1c ≤8.0 444/489 Avoided 45 [17–73] RR: 0.91 (0.85–0.97); 
NNTp: 22 [14–61]#
4,734 (1 RCT) (24)
MACE**; subgroup: HbA1c >8.0 554/507 Excessive 47 
[19–76]
RR: 1.09 (1.04–1.15); 
NNT: 21 (53–13)†
4,734 (1 RCT) (24)
Mortality due to congestive heart 
failure*
5/4 NS RR: 1.10 (0.47–2.59) 4,734 (1 RCT) (24)
Mortality due to fatal arrhythmia* 1/1 NS RR: 1.00 (0.14–7.12) 4,734 (1 RCT) (24)
Mortality related to diabetes* 108/159 Avoided 51 [8–93] RR: 0.68 (0.50–0.92); 
NNTp: 20 [11–120]#
1,148 (1 RCT) (25)
Adverse Events from blood-
pressure medications*
33/13 Excessive 20 
[11–28]
RR: 2.58 (1.70–3.91); 
NNT: 50 [35–87]†
4,733 (1 RCT) (24)
Abnormal Q waves in ECG* 175/231 Avoided 55 [5–105] RR: 0.76 (0.60–0.96); 
NNTp: 18 [10–182]#
1,148 (1 RCT) (25)
Table 3 (continued)
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comparator per 1,000 
Attributable avoided 
events per 1,000 
treated (95% CI)
Relative measure of 
association; number 
needed to treat (95% CI)
No. of participants 
(studies)
Abnormal Q, ST, or T waves in 
ECG*
38/77 Avoided 39 [9–68] RR: 0.50 (0.30–0.82); 
NNTp: 26 [15–112]#
1,148 (1 RCT) (25)
Angina* 59/56 NS RR: 1.05 (0.64–1.73) 1,148 (1 RCT) (25)
Left ventricular hypertrophy* 17/30 Avoided 13 [4–22] RR: 0.58 (0.39–0.86); 
NNTp: 79 [46–273]#
4,331 (1 RCT) (43)
Any diabetes-related end point** 342/436 Avoided 94 [35–154] RR: 0.78 (0.67–0.91); 
NNTp: 11 [6–29]#
1,148 (1 RCT) (25)
Macroalbuminuria** 56/78 NR RR: 0.77 (0.63–0.94)# 5,527 (2 RCTs) (24,25)
Microalbuminuria*** 253/296 NS RR: 0.92 (0.85–1.01) 5,527 (2 RCTs) (24,25)
Renal failure* 4/3 NS RR: 1.38 (0.18–10.81) 5,881 (2 RCTs) (24,25)
Peripheral vascular disease* 11/21 NS RR: 0.51 (0.19–1.36) 1,148 (1 RCT) (25)
Cataract extraction* 47/36 NS RR: 1.32 (0.72–2.42) 1,148 (1 RCT) (25)
Vision preventing driving * 42/62 NS RR: 0.69 (0.41–1.15) 1,148 (1 RCT) (25)
Vitreous hemorrhage* 4/13 NS RR: 0.31 (0.07–1.29) 1,148 (1 RCT) (25)
Falls* 200/206 NS RR: 0.97 (0.84–1.11) 3,099 (1 RCT) (44)
Fatal accident* 1/3 NS RR: 0.51 (0.03–8.20) 1,148 (1 RCT) (25)
Fatal accident/trauma* 2/1 NS RR: 2.51 (0.49–12.92) 4,734 (1 RCT) (24)
All non-spine bone fractures* 76/98 Avoided 23 [3–43] RR: 0.77 (0.61–0.97); 
NNTp: 44 [23–337]#
3,099 (1 RCT) (44)
Ankle fractures* 16/24 NS RR: 0.67 (0.41–1.11) 3,099 (1 RCT) (44)
Distal forearm fractures* 8/8 NS RR: 0.94 (0.43–2.06) 3,099 (1 RCT) (44)
Foot fractures* 6/13 NS RR: 0.46 (0.21–1.01) 3,099 (1 RCT) (44)
Hip fractures* 3/8 NS RR: 0.43 (0.15–1.20) 3,099 (1 RCT) (44)
Proximal humerus fractures* 10/12 NS RR: 0.81 (0.41–1.58) 3,099 (1 RCT) (44)
Hives or swelling* 88/88 NS RR: 1.00 (0.67–1.51) 969 (1 RCT) (24)
Hyperkalemia* 4/0 Excessive 3 [1–6] RR: 9.03 (1.15–71.25); 
NNT: 295 [166–1,299]†
4,733 (1 RCT) (24)
Hypotension* 7/0 Excessive 7 [3–10] RR: 17.06 (2.27–128.12); 
NNT: 148 [97–306]†
4,733 (1 RCT) (24)
Population: adults with diabetes and elevated arterial blood pressure (SBP: 130–190 mmHg); Settings: outpatient; Intervention: intensive 
blood pressure control [target SBP <120 versus <140 mmHg in ACCORD study and 144/82 versus 154/87 mmHg in UKPDS 38 (66) 
study]; Comparator: standard blood pressure control. *, very low quality evidence; **, low quality evidence; ***, moderate quality evidence; 
#, favors lower blood pressure target; †, favors higher blood pressure target; CI, confidence interval; ECG, electrocardiogram; GRADE, 
Grading of Recommendations Assessment, Development and Evaluation; NNT, number needed to treat; NNTp, number needed to treat 
to prevent an outcome in one patient; RCT, randomized controlled trial; RR, relative risk; SBP, systolic blood pressure; MACE, major 
cardiovascular events including nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes.
Aronow and Shamliyan. Blood pressure in diabetes
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Figure 1 Cardiovascular outcomes after intensive versus standard systolic blood pressure control in adults with diabetes mellitus and arterial 
hypertension. Target systolic blood pressure <120 versus <140 mmHg in ACCORD study and 144/82 versus 154/87 mmHg in UKPDS 38 
study. RR, relative risk.
Figure 2 Stroke after intensive versus standard systolic blood pressure control in adults with diabetes mellitus and arterial hypertension. 
Target systolic blood pressure <120 versus <140 mmHg in ACCORD study and 144/82 versus 154/87 mmHg in UKPDS 38 study.
Annals of Translational Medicine, Vol 6, No 11 June 2018 Page 9 of 13
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In addition to healthy lifestyle, recent guidelines 
recommend antihypertensive drug treatments in patients 
with diabetes and baseline blood pressure ≥130/80 mmHg 
(54-56,59-61) .  The American Heart  Associat ion 
recommends a treatment goal of <130/80 mmHg, while the 
American Diabetes Association recommends a treatment 
goal of <140/90 mmHg with lower targets in individuals 
at high risk of cardiovascular disease (54-56,59-61). 
Other guidelines also recommend baseline cardiovascular 
disease risk assessment and evaluation of kidney, eye, or 
cerebrovascular damage in determining individual treatment 
goals (51,62-65). The American Geriatrics Society 
guidelines acknowledge the potential harm from arterial 
hypotension in older adults with diabetes mellitus (66). 
Guidelines generally agree that high quality care for 
patients with diabetes include normalization of HbA1C 
without hypoglycemia (67-69). This definition of high 
quality care for patients with diabetes should include 
normalization of blood pressure including pulse pressure 
without hypotension.
Regardless of the intended blood pressure goal, the 
ability to maintain a lower blood pressure threshold in 
a real-world setting outside of a controlled trial is an 
important disease management consideration (70). It is 
often reported that more than half of treated patients 
are not able to maintain blood pressure control, even at 
a threshold of <140/85 mmHg (71). Findings from the 
DIALOGUE study (72), a multicenter prospective registry 
among patients with hypertension and type II diabetes, 
demonstrated that patients with a “strict” SBP target 
(≤130 mmHg) had more contacts with general practitioners 
than any other patient group. In addition, among patients 
with a lower blood pressure target, only half actually 
maintained this threshold over 6 months. More specifically, 
53% of patients in the “strict” target group (≤130 mmHg) 
were able to maintain this blood pressure goal over 
time, and 55% of patients in the “medium” target group 
(130 to ≤135 mmHg) were able to do so. 
The majority of the studies relied on office measurements 
of blood pressure rather than ambulatory blood pressure 
monitoring. However, ambulatory blood pressure 
monitoring improves baseline and post-treatment risk 
assessment (73-86). Evidence-based guidelines recommend 
ambulatory blood pressure monitoring for diagnosis and 
individualization of treatment goals in adults with arterial 
hypertension (51,56,87-89).
Our review has several limitations. We analyzed direct 
evidence from RCTs that randomly assigned patients to 
more versus less intensive blood pressure goals and did 
not abstract the data from RCTs aimed at efficacy or 
comparative effectiveness of hypotensive drugs. We could 
not reproduce the results from meta-regression, because 
the authors did not provide sufficient data (30,33,35-38,90). 
We did not contact authors of meta-analyses requesting 
reproducible data. We do not know how many unregistered 
and unpublished studies analyzed the association between 
baseline and attained blood pressure and patient outcomes.
Despite this limitation, we present conflicting evidence 
from all published and unpublished studies appraised with 
consistent GRADE methodology. In contrast with previous 
meta-analyses of direct evidence, we grouped studies by 
baseline hypertension status and by targeted diastolic and 
SBP targets (38,40).
Our review has implications for clinical practice. 
Clinicians should assess baseline cardiovascular risk, 
recommend behavioural and pharmacological treatments 
a iming at  b lood pressure  normal izat ion without 
hypotension or orthostatic hypotension (91). They should 
engage patients in life style optimization, blood pressure 
self-monitoring, and monitoring of drug adverse effects (92).
Our review has policy implications. High quality care in 
patients with diabetes and arterial hypertension should be 
defined as achievement of normal blood pressure without 
episodes of hypotension and with minimal risk of orthostatic 
hypotension or other serious harms from recommended drugs.
Our review has research implications. Future research 
should determine the optimal blood pressure targets in 
subpopulations with diabetes and various demographic, 
socioeconomic, and behavioral factors,  as well  as 
comorbidities. Composite outcomes should be avoided. 
Trials should use blood pressure monitoring and examine 
pulse pressure, the risk of orthostatic hypotension and other 
drug-related harms in determining optimal choice of drugs 
and blood pressure targets in individual patients. 
Conclusions
Based on our review, we conclude that in adults with 
diabetes and arterial hypertension, in order to reduce 
the risk of stroke, left ventricular hypertrophy and ECG 
abnormalities, macroalbuminuria, and non-spine bone 
fractures, clinicians should encourage healthy lifestyle 
choices and antihypertensive medications targeting blood 
pressure of 120–130/80 mmHg, with close monitoring of 
Aronow and Shamliyan. Blood pressure in diabetes
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daily blood pressure fluctuations, episodes of orthostatic 
hypotension, and other drug-related harms.
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Supplementary
PICO question this report is addressing: 
What are the benefits and harms of “lower” blood 
pressure targets compared to “standard” blood pressure 
targets in high-risk diabetic patients?
Population Adults with type 2 diabetes 
Baseline blood pressure
Patient demographics, socioeconomic status, 
smoking, physical activity, diet (sodium intake), 
prior treatment and response to medications 
for hypertension, comorbidities (e.g., cardiac 
arrhythmias, obesity, diabetes, asthma, chronic 
obstructive pulmonary disease), concomitant 
and concurrent medications
Intervention Lower blood pressure targets as defined in the 
studies





Cardiovascular disease (CVD) events (stroke, 





Participants Adults with type 2 diabetes 
Language restrictions English
Publication dates (from and to) 
for searching
2010–2018 (published high-
quality reviews should 
address early publications 
of randomized trials)
Inclusion of guidelines ECRI institute (formerly the 
“Emergency Care Research 
Institute”) appraised, 
published since 2010
Meeting Institute of 
Medicine criteria for 
trustworthy guidelines
Inclusion of clinical performance 
measures
Yes
Inclusion for systematic reviews 
(review quality, reviews with 
quantitative analyses)
Yes
Inclusion of randomized trials Yes, published since 2010
Inclusion of observational studies 
for harms (study characteristics, 
design, applicability, sample size, 
statistical methods to reduce 
bias)
Nationally representative 
prospective cohort studies 
of adverse effects with 
multivariate adjustment of 
adverse effects
Exclusion criteria
Interventions We exclude trials of interventions at adults 
without diabetes
Outcomes Intermediate outcomes such as hemodynamic 
characteristics
Study design Uncontrolled case series or uncontrolled 
clinical trials
Meeting abstracts presenting the results of 
randomized controlled trials (RCT) that have 
been published in peer-reviewed journals or 
have results in clinicaltrials.gov
Search strategy
The medical librarian develops specific search strategies 
based on the PICOs formulated by our clinical and 
epidemiology staff. We search for all relevant articles 
published in English from 2010 up to March 2018 in 
PubMed, EMBASE, and the Cochrane Library. To identify 
grey unpublished data, we conduct a search of the trial 
registry clinicaltrials.gov. 
We conduct the following searches: 
PubMed searches for:
(I) RCTs;
(II) Observational studies of harms (multivariate 
adjusted estimates from nationally representative 
cohorts or administrative databases) (6,7);
(III) Clinical practice guidelines.
EMBASE searches for full publications of:
(I) RCTs;
(II) Observational studies (multivariate adjusted 
estimates from nationally representative cohorts or 
administrative databases).
The bibliographies of identified articles are scanned, and 
study investigators are contacted for additional publications. 
Study selection
The study epidemiologist and an author-subject matter 
expert contribute equally to resolving differences and decide 
the determination of eligibility collaboratively.
The study epidemiologist and an author-subject matter 
expert determine eligibility for full text review, first screen 
title, and abstracts. All citations found during the searches 
are stored in a reference database.
Data extraction and strategy for data synthesis
Data extraction
The data  was  extracted from the Cl inica l  Tria ls 
Transformation Initiative (https://www.ctti-clinicaltrials.
org/aact-database), checked for quality, and stored in the 
HPCC platform (High-Performance Computing Cluster, 
https://hpccsystems.com/). 
We manually abstracted the data from published 
articles into the abstraction form. We checked the data for 
ambiguity (i.e., data reported in percentiles conflicting with 
unit data and vice versa; values outside a normal range) and 
mismatch with the published data. Identified errors have 
been discussed and corrected.  
We abstract the information about study population, 
interventions, comparators, and outcomes. We abstract 
minimum datasets (e.g., number of the subjects in treatment 
groups and events) to estimate absolute risk difference, relative 
risk, and number needed to treat for categorical variables.
Means and standard deviations of continuous variables, e.g., 
total scores from the quality of life scales are abstracted. Statistical 
significance is evaluated at a 95% confidence level (including the 
use of P values). All authors have access to the data.
We conduct an overview of the reviews following the 
framework of the Cochrane Collaboration. We perform meta-
analyses or update published meta-analyses. Pooling criteria 
include the exact same definitions of the active and control 
intervention, patient outcomes, and similar follow-up time (10).
We define harms as the totality of all possible adverse 
consequences of an intervention. Investigators sometimes 
defined harmful effects as unrelated to examined treatments. 
Harms are analyzed regardless of how investigators related 
them to treatments.
We calculate absolute risk difference, number needed 
to treat, and the number of attributable events based on 
data from the published randomized trials, using STATA 
software. Correction coefficients for zero events are used as 
a default option in both software programs, and intention 
to treat is used for evidence synthesis. Superiority of 
interventions under comparison is hypothesized.
We assess reporting bias as a proportion of published 
among all registered studies, unreported outcomes 
compared with published protocols, or unreported 
minimum data sets for reproducibility of the results. We did 
not conduct formal statistical tests for publication bias due 
to the questionable validity of such tests (18).
To examine the role of patient characteristics, a search is 
undertaken for subgroup analyses by patient demographics, 
baseline and achieved blood pressure, prior treatment 
response, and comorbidities in systematic reviews and 
randomized trials, including significant interaction effects.
Methodological assessment of the included studies
For systematic reviews (QIRs), we use the Assessment of 
Multiple Systematic Reviews (AMSTAR) scale to determine 
the methodological strength of the systematic reviews (99).
For randomized studies, we apply the Cochrane risk of 
bias tool. Risk of bias is assessed on a 3-point scale: high 
bias, low bias, and unclear (100,101). A low risk of bias 
is assumed when RCTs met all the risk-of-bias criteria, a 
medium risk of bias if at least 1 of the risk-of-bias criteria 
is not met, and a high risk of bias if 2 or more risk-of-bias 
criteria are not met. An unknown risk of bias is assigned for 
the studies with poorly reported risk-of-bias criteria. We 
assign high risk of bias to all observational studies.
For clinical practice guidelines, we use the Appraisal of 
Guidelines for Research and Evaluation (AGREE) II (2009) 
tool, which covers 23 items in 6 domains and 2 overall 
global ratings (102,103).
Quality assessment of the included studies and 
the body of evidence by outcome according to 
the GRADE framework
The authors assign the quality of evidence ratings as high, 
moderate, low, or very low, according to risk of bias in the 
body of evidence, directness of comparisons, precision and 
consistency in treatment effects, and the evidence of reporting 
bias, using Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) methodology (23). 
We upgrade the risk of bias from low to high if at least 1 RCT 
had high risk of bias. We define indirectness in outcomes from 
intermediate outcomes. We review published network meta-
analyses but do not conduct indirect comparisons.
Treatment effect estimates are defined as precise when pooled 
estimates have reasonably narrow 95% confidence intervals and 
the number of events are greater than 250. Justification of the 
sample size is not included in grading of the evidence. We do 
not conduct post hoc statistical power analyses.
In assessing the quality of evidence in all studies, the 
authors look for a dose response association, the strength 
of association, and evidence of any reporting bias. The 
strength of the association is evaluated, defining a priori a 
large effect when the relative risk is greater than 2 and a 
very large effect when the relative risk is greater than 5. A 
small treatment effect is construed when the relative risk 
was significant but less than 2. For standardized continuous 
measures of secondary and intermediate outcomes, the 
magnitude of the effect is defined according to Cohen et al. 
as small, moderate, and large, corresponding to mean 
differences in standard deviation units of 0 to 0.5, 0.5 to 0.8, 
and greater than 0.8, respectively.
A high quality of evidence is assigned to well-designed RCTs 
with consistent findings. The quality of evidence is downgraded 
to moderate if at least 1 of 4 quality of evidence criteria is not 
met; for example, moderate quality of evidence is assigned if 
there was a high risk of bias in the body of evidence or if the 
results are not consistent or precise. The quality of evidence is 
downgraded to low if 2 or more criteria are not met.
A low quality of evidence is assigned to nonrandomized 
studies and upgraded for the rating if there was a strong 
or dose-response association. Evidence is defined as 
insufficient when no studies provided valid information 
about treatment effects. This approach is applied regardless 
of whether the results were statistically significant.
The authors assign strength of the recommendations 
based on overall quality of evidence, balances between 
benefits and harms, healthcare consumers’ and clinicians’ 
values and preferences, and cost-effectiveness studies using 
the GRADE methodology.
Grade Definition
High We are very confident that the estimate of effect lies 
close to the true effect for this outcome. The body of 
evidence has few or no deficiencies. We believe that 
the findings are stable, i.e., another study would not 
change the conclusions
Moderate We are moderately confident that the estimate of effect 
lies close to the true effect for this outcome. The body 
of evidence has some deficiencies. We believe that the 
findings are likely to be stable, but some doubt remains 
Low We have limited confidence that the estimate of effect 
lies close to the true effect for this outcome. The body 
of evidence has major or numerous deficiencies (or 
both). We believe that additional evidence is needed 
before concluding either that the findings are stable or 
that the estimate of effect is close to the true effect 
Very low We have very little confidence in the effect estimate: 
the true effect is likely to be substantially different from 
the estimate of the effect. Any estimate of effect is very 
uncertain
Insufficient We have no evidence, we are unable to estimate an 
effect, or we have no confidence in the estimate of 
effect for this outcome. No evidence is available or 
the body of evidence has unacceptable deficiencies, 
precluding reaching a conclusion
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Figure S1 Study flow diagram. Publications of primary RCTs of blood pressure targets (24-29,42-44,104-107); publications of RCTs that 
examined efficacy or comparative effectiveness of antihypertensive drugs in 1970–1989 (108-114), 1990–1999 (41,115-135), 2000–2002 
(136-152), 2003–2005 (153-174), 2006–2009 (175-190), 2010–2014 (191-207); publications of reviews (3-5,30,31,33-38,40,50,90,93,208,209); 
publications of guidelines published in 2010–2014 (59,60,62-66,94,95,97,210-213) and in 2015–2018 (51-56,61,87,96,98,214-217).
306 references were identified 
through database searching
306 references after removing duplicates
306 records screened
183 of full-text articles assessed for 
eligibility including 38 guidelines and 
expert consensus
123 of records 
excluded
33 of full-text 
articles 
16 publications of systematic 
reviews and meta-analyses and 96 
publications of RCTs
6 RCTs that directly compared 
outcomes between blood pressure 
targets
47 references were found from 
manual searchers or publications of 
the registered studies
Table S1 Relative risk of patient outcomes depending on baseline or attained blood pressure in adults with diabetes, the results from meta-
analyses of aggregate data from randomized controlled clinical trials
Outcome Blood pressure Relative risk No. of participants (studies)
Meta-regression of aggregate data by baseline blood pressure 
All-cause mortality 10 mmHg lower baseline SBP 1.04 (0.98–1.10) 73,738 (49 RCTs) (31)
All-cause mortality 10 mmHg lower baseline DBP 1.08 (0.99–1.18) 73,738 (49 RCTs) (31) 
Cardiovascular mortality 10 mmHg lower baseline SBP 1.15 (1.03–1.29) 73,738 (49 RCTs) (31)
Cardiovascular mortality 10 mmHg lower baseline DBP 1.28 (1.05–1.55) 73,738 (49 RCTs) (31)
End-stage renal disease 10 mmHg lower baseline SBP 1.05 (0.90–1.22) 73,738 (49 RCTs) (31)
End-stage renal disease 10 mmHg lower baseline DBP 1.13 (0.88–1.44) 73,738 (49 RCTs) (31)
Heart failure 10 mmHg lower baseline SBP 1.05 (0.93–1.20) 73,738 (49 RCTs) (31)
Heart failure 10 mmHg lower baseline DBP 1.11 (0.90–1.36) 73,738 (49 RCTs) (31)
Myocardial infarction 10 mmHg lower baseline SBP 1.12 (1.03–1.22) 73,738 (49 RCTs) (31)
Myocardial infarction 10 mmHg lower baseline DBP 1.11 (0.98–1.26) 73,738 (49 RCTs) (31)
Stroke 10 mmHg lower baseline SBP 1.07 (0.98–1.18) 73,738 (49 RCTs) (31)
Stroke 10 mmHg lower baseline DBP 1.09 (0.93–1.27) 73,738 (49 RCTs) (31)
Subgroup meta-analysis of aggregate data by baseline blood pressure
All-cause mortality Baseline SBP >150 mmHg 0.89 (0.80–0.99) 12,824 (16 RCTs) (31)
Cardiovascular mortality Baseline SBP >150 mmHg 0.75 (0.57–0.99) 9,073 (11 RCTs) (31)
Myocardial infarction Baseline SBP >150 mmHg 0.74 (0.63–0.87) 9,914 (13 RCTs) (31)
Stroke Baseline SBP >150 mmHg 0.77 (0.65–0.91) 11,444 (15 RCTs) (31)
Heart failure Baseline SBP >150 mmHg 0.73 (0.53–1.01) 6,510 (7 RCTs) (31)
End-stage renal disease Baseline SBP >150 mmHg 0.82 (0.71–0.94) 4,814 (5 RCTs) (31)
All-cause mortality Baseline SBP 140–150 mmHg 0.87 (0.78–0.98) 24,652 (10 RCTs) (31)
All-cause mortality Baseline SBP >140mmHg 0.73 (0.64–0.84) 30,998 (13 RCT) (93)
Cardiovascular mortality Baseline SBP 140–150 mmHg 0.87 (0.71–1.05) 24,243 (9 RCTs) (31)
Cardiovascular disease Baseline SBP >140mmHg 0.74 (0.65–0.85) 29,044 (11RCT) (93)
Myocardial infarction Baseline SBP 140–150 mmHg 0.84 (0.76–0.93) 23,286 (7 RCTs) (31)
Stroke Baseline SBP 140–150 mmHg 0.92 (0.83–1.01) 30,135 (9 RCTs) (31)
Stroke Baseline SBP >140mmHg 0.74 (0.74–0.86) 36,934 (14 RCT) (93)
Heart failure Baseline SBP 140–150 mmHg 0.80 (0.66–0.97) 12,723 (7 RCTs) (31)
End-stage renal disease Baseline SBP 140–150 mmHg 0.91 (0.74–1.12) 21,376 (6 RCTs) (31)
All-cause mortality Baseline SBP <140 mmHg 1.05 (0.95–1.16) 24,350 (14 RCTs) (31)
All-cause mortality Baseline SBP <140 mmHg 1.07 (0.92–1.26) 12,559 (7 RCTs) (93)
Cardiovascular mortality Baseline SBP <140 mmHg 1.15 (1.00–1.32) 22,439 (10 RCTs) (31)
Cardiovascular disease Baseline SBP <140 mmHg 0.96 (0.88–1.05) 21,574 (6 RCTs) (93)
Myocardial infarction Baseline SBP <140 mmHg 1.00 (0.87–1.15) 18,051 (9 RCTs) (31)
Stroke Baseline SBP <140 mmHg 0.81 (0.53–1.22) 17,911 (8 RCTs) (31)
Stroke Baseline SBP <140 mmHg 0.69 (0.69–0.92) 17,127 (5 RCT) (93)
Heart failure Baseline SBP <140 mmHg 0.90 (0.79–1.02) 17,392 (8 RCTs) (31)
End-stage renal disease Baseline SBP <140 mmHg 0.97 (0.80–1.17) 19,973 (7 RCTs) (31)
Cardiovascular mortality Baseline SBP <130 mmHg 2.95 (0.43–20.20) 4,946 (2 RCTs) (37)
All-cause mortality Baseline DBP >90 mmHg 0.85 (0.73–1.00) 6,591 (9 RCTs) (31)
Cardiovascular mortality Baseline DBP >90 mmHg 0.70 (0.55–0.89) 4,452 (6 RCTs) (31)
Myocardial infarction Baseline DBP >90 mmHg 0.79 (0.62–1.00) 3,681 (6 RCTs) (31)
Stroke Baseline DBP >90 mmHg 0.74 (0.58–0.94) 5,211 (8 RCTs) (31)
Heart failure Baseline DBP >90 mmHg 0.50 (0.29–0.85) 1,259 (2 RCTs) (31)
End-stage renal disease Baseline DBP >90 mmHg 0.96 (0.14–6.76) 1,259 (2 RCTs) (31)
All-cause mortality Baseline DBP 80–90 mmHg 0.90 (0.82–0.99) 25,779 (16 RCTs) (31)
Cardiovascular mortality Baseline DBP 80–90 mmHg 0.91 (0.78–1.07) 24,842 (13 RCTs) (31)
Myocardial infarction Baseline DBP 80–90 mmHg 0.85 (0.76–0.95) 24,861 (13 RCTs) (31)
Stroke Baseline DBP 80–90 mmHg 0.92 (0.83–1.03) 30,604 (14 RCTs) (31)
Heart failure Baseline DBP 80–90 mmHg 0.81 (0.67–0.97) 13,322 (11 RCTs) (31)
End-stage renal disease Baseline DBP 80–90 mmHg 0.83 (0.72–0.94) 20,912 (8 RCTs) (31)
All-cause mortality Baseline DBP <80 mmHg 0.97 (0.89–1.06) 29,456 (15 RCTs) (31)
Cardiovascular mortality Baseline DBP <80 mmHg 1.08 (0.82–1.41) 27,091 (11 RCTs) (31)
Myocardial infarction Baseline DBP <80 mmHg 0.90 (0.79–1.02) 22,709 (10 RCTs) (31)
Stroke Baseline DBP <80 mmHg 0.86 (0.70–1.05) 23,675 (10 RCTs) (31)
Heart failure Baseline DBP <80 mmHg 0.89 (0.80–1.00) 22,044 (9 RCTs) (31)
End-stage renal disease Baseline DBP <80 mmHg 0.97 (0.83–1.13) 23,992 (8 RCTs) (31)
Meta-regression of aggregate data by attained blood pressure
All-cause mortality Each 10 mmHg lower attained SBP 0.94 (0.89–0.99) 53,344 (20 RCTs) (33)
All-cause mortality Each 10 mmHg lower attained SBP 1.02 (0.93–1.12) 73,738 (49 RCTs) (31)
All-cause mortality Each 10 mmHg lower attained DBP 1.07 (0.93–1.23) 73,738 (49 RCTs) (31)
Cardiovascular mortality Each 10 mmHg lower attained SBP 1.20 (0.99–1.44) 73,738 (49 RCTs) (31)
Cardiovascular mortality Each 10 mmHg lower attained DBP 1.35 (0.98–1.86) 73,738 (49 RCTs) (31)
Coronary heart disease Each 10 mmHg lower attained SBP 0.88 (0.80–0.97) 52,129 (19 RCTs) (33)
Major cardiovascular events Each 10 mmHg lower attained SBP 0.88 (0.82–0.94) 59,773 (23 RCTs) (33)
Myocardial infarction Each 10 mmHg lower attained SBP 1.09 (0.98–1.21) 73,738 (49 RCTs) (31)
Myocardial infarction Each 10 mmHg lower attained DBP 1.13 (0.96–1.33) 73,738 (49 RCTs) (31)
Heart failure Each 10 mmHg lower attained SBP 0.90 (0.83–0.98) 41,960 (13 RCTs) (33)
Heart failure Each 10 mmHg lower attained SBP 1.05 (0.90–1.22) 73,738 (49 RCTs) (31)
Heart failure Each 10 mmHg lower attained DBP 1.11 (0.90–1.36) 73,738 (49 RCTs) (31)
End-stage renal disease Each 10 mmHg lower attained SBP 1.02 (0.85–1.24) 73,738 (49 RCTs) (31)
End-stage renal disease Each 10 mmHg lower attained DBP 1.11 (0.88–1.41) 73,738 (49 RCTs) (31)
Renal failure Each 10 mmHg lower attained SBP 0.92 (0.84–1.01) 28,190 (9 RCTs) (33)
Stroke Each 10 mmHg lower attained SBP 0.74 (0.65–0.84) 58,064 (21 RCTs) (33)
Stroke Each 10 mmHg lower attained SBP 0.97 (0.82–1.13) 73,738 (49 RCTs) (31)
Stroke Each 10 mmHg lower attained DBP 0.95 (0.75–1.21) 73,738 (49 RCTs) (31)
Subgroup meta-analysis of aggregate data by attained blood pressure
All-cause mortality – 0.92 (0.87–0.96) 66,130 (45 RCTs) (31)
All-cause mortality Attained SBP >140 0.96 (0.86–1.06) 21,876 (13 RCTs) (31)
All-cause mortality** Attained SBP ≥140 0.98 (0.89–1.07) 11,559 (9 RCTs) (37)
All-cause mortality** Attained SBP 130–139 0.85 (0.78–0.92) 23,714 (11 RCTs) (37)
All-cause mortality* Attained SBP 130–139 0.81 (0.49–1.35) 1,654 (4 RCTs) (37)
All-cause mortality Attained SBP 130–140 0.86 (0.79–0.93) 28,900 (18 RCTs) (31)
All-cause mortality** Attained SBP <130 1.00 (0.82–1.21) 6,117 (2 RCTs) (37)
All-cause mortality* Attained SBP <130 1.44 (0.81–2.57) 4,946 (2 RCTs) (37)
All-cause mortality Attained SBP <130 1.10 (0.91–1.33) 11,050 (9 RCTs) (31)
All-cause mortality Attained DBP >80 mmHg 0.95 (0.86–1.06) 13,092 (13 RCTs) (31)
All-cause mortality Attained DBP 75–80 mmHg 0.86 (0.75–0.98) 14,059 (13 RCTs) (31)
All-cause mortality Attained DBP <75 0.97 (0.89–1.04) 34,675 (14 RCTs) (31)
Cardiovascular mortality – 0.92 (0.82–1.03) 59,956 (33 RCTs) (31)
Cardiovascular mortality Attained SBP >140 0.87 (0.71–1.07) 20,703 (11 RCTs) (31)
Cardiovascular mortality** Attained SBP ≥140 0.92 (0.75–1.13) 10,386 (10 RCTs) (37)
Cardiovascular mortality** Attained SBP 130–139 0.79 (0.67–0.93) 22,942 (7 RCTs) (37)
Cardiovascular mortality* Attained SBP 130–139 0.61 (0.15–2.47) 2459 (4 RCTs) (37)
Cardiovascular mortality Attained SBP 130–140 0.86 (0.72–1.04) 25,095 (12 RCTs) (31)
Cardiovascular mortality** Attained SBP <130 1.12 (0.77–1.63) 6,117 (2 RCTs) (37)
Cardiovascular mortality Attained SBP <130 mmHg 1.26 (0.89–1.77) 10,587 (7 RCTs) (31)
Cardiovascular mortality Attained DBP >80 mmHg 0.71 (0.53–0.97) 11,229 (10 RCTs) (31)
Cardiovascular mortality Attained DBP 75–80 mmHg 0.85 (0.69–1.05) 13,040 (10 RCTs) (31)
Cardiovascular mortality Attained DBP <75 mmHg 1.16 (0.92–1.47) 32,116 (10 RCTs) (31)
Coronary heart disease** Attained SBP ≥140 0.72 (0.60–0.85) 11,559 (9 RCTs) (37)
Coronary heart disease** Attained SBP 130–139 0.86 (0.78–0.94) 22,942 (10 RCTs) (37)
Coronary heart disease* Attained SBP 130–139 0.67 (0.29–1.55) 1,274 (3 RCTs) (37)
Coronary heart disease* Attained SBP <130 0.67 (0.40–1.14) 4,946 (2 RCTs) (37)
Myocardial infarction – 0.87 (0.81–0.94) 53,512 (31 RCTs) (31)
Myocardial infarction Attained SBP >140 mmHg 0.82 (0.72–0.92) 21,286 (12 RCTs) (31)
Myocardial infarction Attained SBP 130–140 mmHg 0.88 (0.79–0.97) 23,828 (11 RCTs) (31)
Myocardial infarction Attained SBP <130 mmHg 0.94 (0.76–1.15) 6,137 (6 RCTs) (31)
Myocardial infarction Attained DBP >80 mmHg 0.76 (0.63–0.93) 9,608 (8 RCTs) (31)
Myocardial infarction Attained DBP 75–80 mmHg 0.81 (0.72–0.91) 13,650 (12 RCTs) (31)
Myocardial infarction Attained DBP <75 mmHg 0.95 (0.84–1.07) 27,993 (9 RCTs) (31)
Heart failure – 0.82 (0.75–0.89) 40,196 (25 RCTs) (31)
Heart failure Attained SBP >140 mmHg 0.83 (0.68–1.00) 19,060 (9 RCTs) (31)
Heart failure** Attained SBP ≥140 0.86 (0.70–1.05) 8,743 (5 RCTs) (37)
Heart failure Attained SBP 130–140 mmHg 0.81 (0.70–0.94) 11,568 (8 RCTs) (31)
Heart failure** Attained SBP 130–139 0.82 (0.69–0.97) 20,952 (8 RCTs) (37)
Heart failure Attained SBP <130 mmHg 0.93 (0.71–1.21) 5,997 (5 RCTs) (31)
Heart failure** Attained SBP <130 0.89 (0.65–1.23) 6,117 (2 RCTs) (37)
Heart failure Attained DBP >80 mmHg 0.72 (0.45–1.15) 7,656 (5 RCTs) (31)
Heart failure Attained DBP 75–80 mmHg 0.79 (0.65–0.96) 11,135 (9 RCTs) (31)
Heart failure Attained DBP <75 mmHg 0.90 (0.79–1.01) 17,834 (8 RCTs) (31)
Stroke – 0.87 (0.79–0.96) 59,490 (32 RCTs) (31)
Stroke** Attained SBP ≥140 mmHg 0.89 (0.74–1.07) 11,730 (10 RCTs) (37)
Stroke Attained SBP >140 mmHg 0.90 (0.76–1.06) 22,045 (14 RCTs) (31)
Stroke Attained SBP 130–140 mmHg 0.91 (0.83–1.00) 30,342 (12 RCTs) (31)
Stroke** Attained SBP 130–139 0.85 (0.75–0.96) 28,685 (11 RCTs) (37)
Stroke* Attained SBP 130–139 0.89 (0.45–1.78) 1,274 (3 RCTs) (37)
Stroke** Attained SBP <130 0.66 (0.49–0.88) 5,839 (3 RCTs) (37)
Stroke* Attained SBP <130 1.36 (0.55–3.39) 4,946 (2 RCTs) (37)
Stroke Attained SBP <130 mmHg 0.65 (0.42–0.99) 7,103 (6 RCTs) (31)
Stroke Attained DBP >80 mmHg 0.87 (0.73–1.04) 11,011 (10 RCTs) (31)
Stroke Attained DBP 75–80 mmHg 0.86 (0.75–0.97) 19,380 (12 RCTs) (31)
Stroke Attained DBP <75 mmHg 0.87 (0.70–1.08) 29,099 (10 RCTs) (31)
Stroke + CHD** Attained SBP ≥140 0.80 (0.71–0.90) 11,568 (9 RCTs) (37)
Stroke + CHD** Attained SBP 130–139 0.85 (0.78–0.91) 25,060 (11 RCTs) (37)
Stroke + CHD* Attained SBP 130–139 0.73 (0.51–1.04) 2,858 (5 RCTs) (37)
Stroke + CHD* Attained SBP <130 0.80 (0.51–1.26) 4,946 (2 RCTs) (37)
Stroke + CHD + HF** Attained SBP ≥140 0.85 (0.74–0.97) 9,003 (7 RCTs) (37)
Stroke + CHD + HF** Attained SBP 130–139 0.87 (0.80–0.94) 30,032 (12 RCTs) (37)
Stroke + CHD + HF* Attained SBP <130 0.84 (0.60–1.19) 862 (2 RCTs) (37)
End-stage renal disease – 0.88 (0.80–0.97) 47,439 (18 RCTs) (31)
End-stage renal disease Attained SBP >140 mmHg 0.88 (0.76–1.03) 18,287 (7 RCTs) (31)
End-stage renal disease Attained SBP 130–140 mmHg 0.84 (0.66–1.07) 17,912 (6 RCTs) (31)
End-stage renal disease Attained SBP <130 mmHg 1.01 (0.71–1.43) 9,964 (5 RCTs) (31)
End-stage renal disease Attained DBP >80 mmHg 0.77 (0.39–1.52) 6,171 (3 RCTs) (31)
End-stage renal disease Attained DBP 75–80 mmHg 0.81 (0.71–0.93) 8,437 (7 RCTs) (31)
End-stage renal disease Attained DBP <75 mmHg 0.98 (0.84–1.14) 31,555 (8 RCTs) (31)
*, low/moderate cardiovascular risk; **,high/very high cardiovascular risk. CHD, coronary heart disease; DBP, diastolic blood pressure; HF, 
heart failure; RCT, randomized controlled trial; RR, relative risk; SBP, systolic blood pressure.
Table S3 Guideline recommendations regarding blood pressure targets in adults with diabetes
Organization Recommendations
World Health Organization (WHO); A Global Brief on 
Hypertension, 2013 (4,94)
This guideline recommends that target blood pressure in patients with 
diabetes should be <130/80 mmHg
Eighth Joint National Committee (JNC 8). Evidence-based 
Guideline for the Management of High Blood Pressure in 
Adults: Report from the Panel Members Appointed  
to the JNC 8, 2014 (53,95) (AGREE II score: 78%) 
This guideline recommends initiating pharmacologic treatment to lower 
blood pressure at SBP 140 mmHg or DBP 90 mmHg and treat to a goal 
of SBP <140/90 mmHg in all adults with diabetes
AHA/ASA Guidelines for the Prevention of Stroke in Patients 
With Stroke or Transient Ischemic Attack: A Guideline 
for Healthcare Professionals from the American Heart 
Association/American Stroke Association, 2011–2017 (56,59)
This guideline recommends that in adults with diabetes and hypertension, 
antihypertensive drug treatment should be initiated at a blood pressure 
of 130/80 mmHg or higher with a treatment goal of <130/80 mmHg
American Diabetes Association. Position Statement on the 
Standards of Medical Care in Diabetes, 2018 (54,55,60,61) 
(AGREE II score not available)
This guideline recommends that most patients with diabetes and 
hypertension should be treated to an SBP goal of <140/90 mmHg; lower 
SBP and DBP targets, such as 130/80 mmHg, may be appropriate for 
individuals at high risk of cardiovascular disease, if they can be achieved 
without undue treatment burden
American Association of Clinical Endocrinologists and 
American College of Endocrinology. Clinical Practice 
Guidelines for Developing a Diabetes Mellitus Comprehensive 
Care Plan, 2015 (96) (AGREE II score: 53%)
The blood pressure goal for persons with diabetes mellitus or 
prediabetes should be individualized and should generally be about 
130/80 mmHg; a more intensive goal (e.g., <120/80 mmHg) should be 
considered for some patients, provided this target can be reached safely 
without adverse effects from medication; more relaxed goals may be 
considered for frail patients with complicated comorbidities or those who 
have adverse medication effects
Clinical Practice Guidelines for the Management of 
Hypertension in the Community: A Statement by the 
American Society of Hypertension and the International 
Society of Hypertension Clinical Practice Guidelines for the 
Management of Hypertension in the Community: A Statement 
by the American Society of Hypertension and the International 
Society of Hypertension (97)
This guideline recommends that patients with diabetes should be treated 
to <140/90 mmHg; this guideline acknowledges that other guidelines 
have recommended diagnostic values of 130/80 mmHg for patients with 
diabetes or chronic kidney disease. However, the clinical benefits of 
this lower target have not been established; some experts recommend 
<130/80 mmHg if albuminuria is present in patients with comorbid 
chronic kidney disease
The American Geriatrics Society Guidelines for Improving the 
Care of Older Adults With Diabetes Mellitus, 2013 (66)
This guideline states that if an older adult has diabetes and requires 
medical therapy for hypertension, then the target blood pressure should 
be less than 140/90 mmHg if it is tolerated; there is potential harm in 
lowering SBP to less than 120 mmHg in older adults with type 2 diabetes 
mellitus (1B)
American Academy of Family Physicians, 2017 (98) The AAFP continues to endorse the 2014 Evidence-Based Guidelines for 
the Management of High Blood Pressure in Adults, developed by panel 
members appointed to the Eighth Joint National Committee, with a blood 
pressure target of <140/80 mmHg
2013 ESH/ESC Guidelines for the Management of Arterial 
Hypertension: The Task Force for the Management of Arterial 
Hypertension of the European Society of Hypertension (ESH) 
and of the European Society of Cardiology (ESC) (65)
This guideline recommends an SBP goal of <140/90 mmHg in patients 
with diabetes
The National Institute for Health and Care Excellence,  
2011 (63); Type 2 Diabetes in Adults: Management, 2015 (51)
This guideline recommends treating adults with type 2 diabetes and 
arterial hypertension to achieve blood pressure <140/80 mmHg  
(<130/80 mmHg if there is kidney, eye, or cerebrovascular damage)
Scottish Intercollegiate Guidelines Network. Management of 
Diabetes: A National Clinical Guideline (62)  
(AGREE II score: 88%)
This guideline recommends target blood pressure <130/80 mmHg in 
patients with diabetes; in patients with diabetes and kidney disease, 
blood pressure should be reduced to the lowest achievable level to slow 
the rate of decline of glomerular filtration rate and reduce proteinuria
Canadian Hypertension Education Program (CHEP) Guidelines 
for Pharmacists, 2013 (64)
This guideline recommends that patients with kidney disease and 
concomitant diabetes should be treated to a target of <130/80 mmHg
Table S2 GRADE summary of findings. Harms of blood pressure control in adults with diabetes mellitus (low-quality evidence from published 
aggregate data meta-analyses of any antihypertensive treatments)
Outcome
Risk with intervention 
per 1,000 (95% CI)
Risk with comparator 
per 1,000
Relative measure of 
association 
No. of participants 
(studies)
Cardiovascular mortality; baseline 
SBP <130 mmHg
6 2 RR: 3.96 (1.33–11.84); 
2.95 (0.43–20.20)
4,946 (2 RCTs) (37)
Cardiovascular mortality; baseline 
SBP <140 mmHg
NR NR RR: 1.15 (1.00–1.32) 22,439 (10 RCTs) (31)
Cardiovascular mortality; each 10 
mmHg lower baseline SBP
NR NR RR: 1.15 (1.03–1.29) 73,738 (49 RCTs) (31)
Cardiovascular mortality; each 10 
mmHg lower baseline DBP
NR NR RR: 1.28 (1.05–1.55) 73,738 (49 RCTs) (31)
Myocardial infarction; each 10 
mmHg lower baseline SBP
NR NR RR: 1.12 (1.03–1.22) 73,738 (49 RCTs) (31)
Population: adults with diabetes; Settings: outpatient; Intervention: antihypertensive treatment; Comparator: control as no active 
antihypertensive treatment; CI, confidence interval; DBP, diastolic blood pressure; GRADE, Grading of Recommendations Assessment, 
Development and Evaluation; NR, not reported; RCT, randomized controlled trial; RR, relative risk; SBP, systolic blood pressure.
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